Skip to main content
Caplight Logo









Ikaika Therapeutics

Ikaika Therapeutics

Private
Oak Park, IllinoisHealthcare & Life Scienceshttps://ikaikatherapeutics.com/

Last Round

VC Round

Oct 7, 2021

Company Overview

Ikaika Therapeutics operates in Healthcare & Life Sciences and is based in Oak Park, Illinois. Its latest recorded funding round was a VC Round in October 2021.

Ikaika Therapeutics is a biotechnology company that develops first-in-class antibody therapies to prevent fibrosis and preserve organ function in patients with muscular dystrophy and other fibrotic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Ikaika Therapeutics Comparables

Compare Ikaika Therapeutics with similar companies based on industry and business-model similarity.

Ikaika Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tribune Therapeutics
77%
Bristol Myers Squibb
74%
Mediar Therapeutics
72%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Ikaika Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 7, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Ikaika Therapeutics Investors

Notable investors and investment history

Ikaika Therapeutics investors
InvestorRounds
Qral VenturesVC Round

Ikaika Therapeutics Filings

Explore SEC and related filing metadata, where available.

Ikaika Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Ikaika Therapeutics's valuation, stock price, and market status.

Is Ikaika Therapeutics a public or private company?

Ikaika Therapeutics is a private company.

What is the current stock price of Ikaika Therapeutics?

Ikaika Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ikaika Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Ikaika Therapeutics worth (valuation)?

Valuation information for Ikaika Therapeutics is not publicly available.

Can I buy Ikaika Therapeutics stock?

Ikaika Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Ikaika Therapeutics's last funding round?

Ikaika Therapeutics's most recent funding round was VC Round on October 7, 2021.

Who are the main investors in Ikaika Therapeutics?

Key investors in Ikaika Therapeutics include Qral Ventures.

Will Ikaika Therapeutics IPO soon?

No public IPO plans have been announced for Ikaika Therapeutics.

How can I track Ikaika Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Ikaika Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersOak Park, Illinois
Year Founded2021
Last FundingOct 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?